[ad_1] Nano-Capped Therapix Biosciences Therapy (NASDAQ: TRPX) is up from 13% pre-sale on lumen volume in the wake of its announcement of encouraging preclinical results for THX-160 pain, a CB2 receptor agonist. …
Read More »Therapix Bio up 13% pre-commercialization on preclinical data on the lead drug THX-160 – Therapix Biosciences (NASDAQ: TRPX)
